Proxy Votes Now

Home › Funds › Invesco › Invesco Pharmaceuticals ETF

Invesco Pharmaceuticals ETF (PJP) proxy voting record 2025-2026

Fund family: Invesco · Filed by INVESCO EXCHANGE-TRADED FUND TRUST (CIK 1209466) · SEC series S000003031

Ticker: PJP (C000008298)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 322 with, 13 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 12 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Invesco as a whole

The same two figures as Invesco’s manager page (413,145 ballot items across 270 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsInvescoItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)97.8%31694.5%357,245
Backed environmental and social shareholder proposals at US companiesn/a63.1%5,987

Where this fund voted differently from most Invesco funds

Each ballot item this fund voted is set against the votes of the other Invesco funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Invesco funds on all 306 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 97.3% of this fund’s 335 such votes could be given a sector; the other 9 (2.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care326134.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections2360
Say-on-Pay350
Audit-related300
Compensation140
Corporate Governance127
Capital Structure30
Environment or Climate33
Other Social Issues33
Extraordinary Transactions20
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Johnson & JohnsonApril 23, 2026$28M151
AbbVie Inc.May 8, 2026$28M81
Eli Lilly and CompanyMay 4, 2026$27M102
Amgen Inc.May 19, 2026$26M151
Gilead Sciences, Inc.April 30, 2026$24M153
Pfizer Inc.April 23, 2026$23M161
Ligand Pharmaceuticals IncorporatedJune 5, 2026$18M110
Merck & Co., Inc.May 26, 2026$18M183

Notable votes against management

MeetingCompanyProposalFundMgmt
April 23, 2026Johnson & JohnsonIndependent Board Chair Shareholder proposalAgainstFor
May 8, 2026AbbVie Inc.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
May 4, 2026Eli Lilly and CompanyShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026Eli Lilly and CompanyShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 23, 2026Pfizer Inc.Adopt an Independent Chair Policy Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026Merck & Co., Inc.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 5, 2026Bristol-Myers Squibb CompanyShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalAgainstFor

Search this fund’s votes by company

339 ballot items at 31 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Invesco Pharmaceuticals ETF (PJP) voted at 31 shareholder meetings of 30 companies, on 339 ballot items in all. Where management made a recommendation, the fund followed it on 96.1% of the items and voted against it 13 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals more often than Invesco's funds as a whole (97.8% against 94.5%). It voted the same way as most Invesco funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Invesco’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.